Table 1.

Effects of cisplatin or enoxaparin sodium on H357 cell viability (ANOVA test).

Treatment/Time point	Absorbance (% over control)	p-value
	mean ± SD*
Cisplatin/24 h		0.009
1 µM	97.21 ± 27.91
2 µM	89.45 ± 20.53
4 µM	101.51 ± 19.82
8 µM	82.26 ± 12.23
10 µM	80.33 ± 24.92
Cisplatin/48 h		0.001
1 µM	131.92 ± 21.19
2 µM	130.52 ± 19.24
4 µM	115.09 ± 28.51
8 µM	103.69 ± 29.54
10 µM	97.12 ± 44.61
Cisplatin/72 h		0.003
1 µM	110.11 ± 13.66
2 µM	98.65 ± 17.26
4 µM	105.01 ± 14.81
8 µM	107.13 ± 13.78
10 µM	92.61 ± 16.64
Enoxaparin sodium/24 h		0.215
0.1 µg/ml	114.08 ± 15.01
0.5 µg/ml	112.89 ± 20.24
1 µg/ml	112.57 ± 11.37
5 µg/ml	110.33 ± 19.54
10 µg/ml	105.32 ± 20.21
50 µg/ml	102.83 ± 12.78
100 µg/ml	96.07 ± 29.31
Enoxaparin sodium/48 h		0.558
0.1 µg/ml	107.21 ± 18.36
0.5 µg/ml	111.94 ± 21-06
1 µg/ml	114.04 ± 21.57
5 µg/ml	106.41 ± 23.36
10 µg/ml	105.30 ± 16.59
50 µg/ml	108.82 ± 13.61
100 µg/ml	97.76 ± 23.72
Enoxaparin sodium/72 h		0.303
0.1 µg/ml	126.71 ± 33.14
0.5 µg/ml	122.77 ± 25.51
1 µg/ml	113.84 ± 23.14
5 µg/ml	109.31 ± 23.28
10 µg/ml	109.25 ± 17.37
50 µg/ml	108.98 ± 29.21
100 µg/ml	106.18 ± 15.51

*SD, standard deviation.